Viridian Q1 net loss $104.9M; veligrotug PDUFA June 30, elegrobart positive data, BLA Q1 2027

Viridian Therapeutics, Inc.\DE

Cash $762.2M at March 31, 2026, down from $874.7M at Dec 31, 2025; net loss $104.9M vs $86.9M YoY.
Veligrotug BLA under Priority Review with PDUFA target June 30, 2026; launch-ready with hired field teams.
Elegrobart (subcutaneous) met primary endpoints in REVEAL-1 (active TED) and REVEAL-2 (chronic TED); proptosis responder rates 50-63% vs 15-18% placebo.
BLA for elegrobart expected Q1 2027; MAA for veligrotug submitted to EMA and accepted for review.
SG&A jumped to $38.7M from $17.1M due to commercial prep; R&D flat at $77.6M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Viridian Therapeutics, Inc.\DE reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 5, 2026, Viridian Therapeutics, Inc. issued a press release reporting financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-26-205010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.